首页> 外文期刊>Technology in cancer research & treatment. >Hypofractionated stereotactic radiotherapy for brain metastases: a dosimetric and treatment efficiency comparison between volumetric modulated arc therapy and intensity modulated radiotherapy.
【24h】

Hypofractionated stereotactic radiotherapy for brain metastases: a dosimetric and treatment efficiency comparison between volumetric modulated arc therapy and intensity modulated radiotherapy.

机译:用于脑转移的超分割立体定向放射疗法:容积调制弧光疗法与强度调制放射疗法之间的剂量学和治疗效率比较。

获取原文
获取原文并翻译 | 示例
           

摘要

A treatment planning comparison study was performed to evaluate the dosimetric characteristic and treatment efficiency of volumetric modulated arc therapy with step-and-shoot intensity modulated radiotherapy (IMRT) for the hypofractionated stereotactic radiotherapy (HFSRT) in patients with multiple brain metastases. CT datasets of 10 patients with two to four brain metastases were selected for the comparison. Three plans were generated for each case: seven-field step-and-shoot IMRT, single (RA1) and double (RA2) arcs with RapidArc technique (RA, Varian Medical System). The prescribed dose was 50 Gy in 10 fractions and plans were all normalized to the mean dose to the PTV. For PTV, plans aim to achieve at least 98% of PTV was covered with the 95% of prescription dose, at least 95% of PTV was encompassed by the prescription dose, and an over-dosage of 110% of the prescription dose was allowed to 5% volume of the PTV. The plans generated using three techniques were clinically acceptable. The target conformity and homogeneity were improved slightly with RA2 compared to IMRT and RA1. The Paddick CI was 0.868 (IMRT), 0.863 (RA1) and 0.895 (RA2), and HI was 7.7 (IMRT), 7.5 (RA1) and 6.5 (RA2), respectively. Compared with IMRT, the maximum dose in RA2 plans to the brainstem, left and right optic nerves, left and right lens was reduced by 1.6 Gy, 6 Gy, 3 Gy, 1.5 Gy, 1.3 Gy, respectively. The percentage of healthy tissue volume receiving 5 Gy was larger with RA1 (56.7%) and RA2 (57.1%) than with IMRT (52.9%), while the percentages of volume receiving 15 Gy and 20 Gy were smaller with RA1 (27.1%, 18.7%) and RA2 (25%, 16.3%) than with IMRT (28.8%, 19.1%). No significant difference was observed between RA1 and RA2. The mean number of MU per fraction of 5 Gy was 1944 +/- 374 (IMRT), 1199 +/- 173 (RA1) and 1387 +/- 186 (RA2), respectively. Compared with IMRT, the MUs were reduced by 36.8% and 27.2% with RA1 and RA2. The pure beam-on time needed per fraction was 6.5 +/- 1.2 min (IMRT), 1.25 min (RA1) and 2.5 min (RA2), respectively. The beam-on time for RA1 and RA2 was approximately 80% and 40% less compared to IMRT. In conclusion, RA, single arc or double arcs, is a feasible technique with highly conformal dose distribution for the HFSRT in patients with oligo brain metastases. Compared with IMRT, RA1 provides similar plan quality, while RA2 achieves slight improvements in PTV coverage and sparing of organs at risk. The treatment efficiency, using less monitor units and shorter treatment delivery time, is the most obvious advantage.
机译:进行了一项治疗计划比较研究,以评估多发性脑转移患者的分级分割立体定向放射治疗(HFSRT)和逐步射击强度调制放射治疗(IMRT)的容积调制电弧治疗的剂量学特征和治疗效率。选择10例有2至4个脑转移的患者的CT数据集进行比较。针对每种情况生成了三个计划:七场步枪式IMRT,采用RapidArc技术(RA,Varian Medical System)的单弧(RA1)和双弧(RA2)。处方剂量为50 Gy(分10步),所有计划均已标准化为PTV的平均剂量。对于PTV,旨在达到至少98%的PTV被95%的处方剂量覆盖,至少95%的PTV被该处方剂量覆盖并且允许过量使用110%处方剂量的计划到PTV的5%。使用三种技术生成的计划在临床上是可以接受的。与IMRT和RA1相比,RA2的目标一致性和同质性略有改善。 Paddick CI为0.868(IMRT),0.863(RA1)和0.895(RA2),HI分别为7.7(IMRT),7.5(RA1)和6.5(RA2)。与IMRT相比,RA2中脑干,左,右视神经,左和右晶状体的最大剂量分别减少了1.6 Gy,6 Gy,3 Gy,1.5 Gy,1.3 Gy。 RA1(56.7%)和RA2(52.9%)接受5 Gy的健康组织体积百分比大于IMRT(52.9%),而RA1(27.1%, 18.7%)和RA2(25%,16.3%),比IMRT(28.8%,19.1%)高。 RA1和RA2之间没有观察到显着差异。每5 Gy分数的MU平均数分别为1944 +/- 374(IMRT),1199 +/- 173(RA1)和1387 +/- 186(RA2)。与IMRT相比,RA1和RA2的MU分别降低了36.8%和27.2%。每个馏分所需的纯束通时间分别为6.5 +/- 1.2分钟(IMRT),1.25分钟(RA1)和2.5分钟(RA2)。与IMRT相比,RA1和RA2的光束接通时间分别减少了80%和40%。综上所述,RA,单弧或双弧是一种可行的技术,可用于寡脑转移患者的HFSRT具有高度共形的剂量分布。与IMRT相比,RA1提供了类似的计划质量,而RA2则在PTV覆盖范围和有风险的器官保留方面略有改善。最明显的优势是使用更少的监护仪装置和更短的治疗时间即可达到治疗效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号